PH-sensitive and bioreducible polymer-virus complex for cancer treatment
AssigneeGenemedicine Co., Ltd.
InventorsChae Ok Yun, Dayananda Kasala
Life of this patent
Estimating the term…
Abstract
Disclosed is a pH-sensitive and bioreducible polymer-virus complex which can destroy tumor cells more effectively by increasing the efficiency of virus transduction. A pH-sensitive and bioreducible polymer contains (i) an escapable portion from immune reactions, (ii) a chargeable portion having one or more amine groups and (iii) a bioreducible portion including one or more disulfide linkages. The and to a pharmaceutical composition containing the polymer-virus complex. Also disclosed are a pharmaceutical composition containing the pH-sensitive and bioreducible polymer-virus complex and methods for treating cancer in a subject, employing the composition.
Claims4
A method for treating cancer in a subject in need thereof, comprising a step of administering a pharmaceutical composition comprising (a) a therapeutically effective amount of a polymer-virus complex and (b) a pharmaceutically acceptable carrier to the subject,
- wherein a polymer of the polymer-virus complex of (a) is a pH-sensitive and bioreducible polymer, and a virus of the polymer-virus complex of (a) is an oncolytic virus having cancer-specificity, wherein the pH-sensitive and bioreducible polymer is bounded to a surface of the virus;
- and
- wherein the pH-sensitive and bioreducible polymer comprises (i) an escapable portion from immune reactions, (ii) a chargeable portion having one or more amine groups and (iii) a bioreducible portion including one or more disulfide linkages,
- wherein the escapable portion of (i) is bound to the chargeable portion of (ii), and is selected from the group consisting of PEG (polyethylene glycol), mPEG (methoxy polyethylene glycol), and a combination thereof;
- wherein the chargeable portion of (ii) is piperazine or 1-(2-aminoethyl)piperazine;
- wherein the bioreducible portion of (iii) is bound to the chargeable portion of (ii), and is N,N-cystaminebisacrylamide, and
- wherein said pH-sensitive and bioreducible polymer comprises PEI-Arg (polyethyleneimine-arginine) additionally bonded at the end of the bioreducible portion;
- wherein the cancer is selected from the group consisting of breast cancer, pancreatic tumor, lung cancer, uterine cancer, colon cancer, skin cancer, gastric cancer, bone cancer (osteosarcoma), brain stem glioma, bladder cancer, kidney renal cancer, liver cancer, ovarian cancer, cervical cancer, and prostate cancer.
A method for treating a solid tumor in a subject in need thereof, comprising a step of administering a pharmaceutical composition comprising (a) a therapeutically effective amount of a polymer-virus complex and (b) a pharmaceutically acceptable carrier to the subject,
- wherein a polymer of the polymer-virus complex of (a) is a pH-sensitive and bioreducible polymer, and a virus of the polymer-virus complex of (a) is an oncolytic virus having cancer-specificity, wherein the pH-sensitive and bioreducible polymer is bounded to a surface of the virus;
- and
- wherein the pH-sensitive and bioreducible polymer comprises (i) an escapable portion from immune reactions, (ii) a chargeable portion having one or more amine groups and (iii) a bioreducible portion including one or more disulfide linkages,
- wherein the escapable portion of (i) is bound to the chargeable portion of (ii), and is selected from the group consisting of PEG (polyethylene glycol), mPEG (methoxy polyethylene glycol), and a combination thereof;
- wherein the chargeable portion of (ii) is piperazine or 1-(2-aminoethyl)piperazine;
- wherein the bioreducible portion of (iii) is bound to the chargeable portion of (ii), and is N,N-cystaminebisacrylamide;
- and
- wherein said pH-sensitive and bioreducible polymer comprises PEI-Arg (polyethyleneimine-arginine) additionally bonded at the end of the bioreducible portion;
- wherein the solid tumor is selected from the group consisting of breast cancer, pancreatic tumor, lung cancer, uterine cancer, colon cancer, skin cancer, gastric cancer, bone cancer (osteosarcoma), brain stem glioma, bladder cancer, kidney renal cancer, liver cancer, ovarian cancer, cervical cancer, and prostate cancer.
Dependencies are inferred from the claim text.